Summary
ABSTRACT The clinical treatment of autoimmune diseases traditionally uses immunosuppression to curtail the pathogenesis of the autoimmune disease. An alternative for general immune suppression, is antigen specific tolerance. However, there is currently no antigen specific tolerance therapy in the clinics. We have recently discovered serendipitously that degradable microparticles comprised of the biopolymer acetalated dextran (Ace-DEX) can specifically bind to the surface of B cells both in vitro and in vivo. The binding of this biomaterial microparticle to B cells is due to the protein corona
